⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
NLRP3 Inflammasome Inhibitors (MCC950)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-28 — Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.: Preclinical macrophage study reframes NLRP3 in aged cells as a regulator of the apoptosis–senescence balance rather than a cytokine driver; MCC950 blockade reduced apoptosis but increased senescent cell burden (animal-model / cell-level preclinical). [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Beyond Inflammation: The NLRP3 Inflammasome as a Cellular and Mechanical Hub of Vascular Remodeling in Hypertension.
05-oct-2026
novelty 2
per-area 3
introduces
Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.
28-sep-2026
novelty 3
per-area 3
strengthens